Compare
Delcath Systems, Inc. vs Iradimed Corp vs TELA Bio, Inc. vs Pulmonx Corp
| Latest fiscal year | Delcath Systems, Inc. DCTH | Iradimed Corp IRMD | TELA Bio, Inc. TELA | Pulmonx Corp LUNG |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $85.23M | $83.81M | $80.28M | $90.50M |
| Revenue growth (YoY) | +129.1% | +14.4% | +15.8% | +8.0% |
| Gross margin | 86.2% | 76.7% | 67.7% | 74.2% |
| Operating margin | 0.8% | 31.2% | -42.0% | -59.3% |
| Net margin | 3.2% | 26.8% | -48.4% | -59.7% |
| Net income | $2.70M | $22.48M | -$38.83M | -$54.00M |
| EPS (Diluted) | $0.07 | $1.75 | -$0.83 | -$1.33 |
| Operating cash flow | $22.52M | $24.95M | -$28.22M | -$32.38M |
| Free cash flow | $20.97M | $17.18M | -$28.67M | -$32.83M |
| Cash & equivalents | $43.45M | $51.16M | $50.84M | $69.75M |
| Total assets | $123.63M | $108.78M | $81.42M | $129.29M |
| Total liabilities | $12.41M | $14.16M | $75.11M | $75.17M |
| Shareholders' equity | $111.22M | $94.62M | $6.31M | $54.12M |
| Return on year-end equity | 2.4% | 23.8% | -615.1% | -99.8% |
| Shares outstanding | 34.69M | 12.78M | 44.54M | 41.67M |
Revenue, most recent five fiscal years
| Fiscal year | Delcath Systems, Inc. | Iradimed Corp | TELA Bio, Inc. | Pulmonx Corp |
|---|---|---|---|---|
| Latest | $85.23M Ended 2025-12-31 | $83.81M Ended 2025-12-31 | $80.28M Ended 2025-12-31 | $90.50M Ended 2025-12-31 |
| 1 year earlier | $37.20M Ended 2024-12-31 | $73.24M Ended 2024-12-31 | $69.30M Ended 2024-12-31 | $83.79M Ended 2024-12-31 |
| 2 years earlier | $2.06M Ended 2023-12-31 | $65.56M Ended 2023-12-31 | $58.45M Ended 2023-12-31 | $68.67M Ended 2023-12-31 |
| 3 years earlier | $2.72M Ended 2022-12-31 | $53.30M Ended 2022-12-31 | $41.42M Ended 2022-12-31 | $53.66M Ended 2022-12-31 |
| 4 years earlier | $3.56M Ended 2021-12-31 | $41.81M Ended 2021-12-31 | $29.46M Ended 2021-12-31 | $48.42M Ended 2021-12-31 |